Design of the Pregnancy REmote MOnitoring II study (PREMOM II): a multicenter, randomized controlled trial of remote monitoring for gestational hypertensive disorders

Dorien Lanssens, Inge M Thijs, Wilfried Gyselaers, PREMOM II – consortium, Wilfried Gyselaers, Inge M Thijs, Dorien Lanssens, Eric T De Jonge, Caroline Van Holsbeke, Tinne Mesens, Yves Jacquemyn, Dominique Mannaerts, Roland Devlieger, Kristel Van Calsteren, Hilde Logghe, Barbara Lebbe, Dorien Lanssens, Inge M Thijs, Wilfried Gyselaers, PREMOM II – consortium, Wilfried Gyselaers, Inge M Thijs, Dorien Lanssens, Eric T De Jonge, Caroline Van Holsbeke, Tinne Mesens, Yves Jacquemyn, Dominique Mannaerts, Roland Devlieger, Kristel Van Calsteren, Hilde Logghe, Barbara Lebbe

Abstract

Background: Observational data from the retrospective, non-randomized Pregnancy REmote MOnitoring I (PREMOM I) study showed that remote monitoring (RM) may be beneficial for prenatal observation of women at risk for gestational hypertensive disorders (GHD) in terms of clinical outcomes, health economics, and stakeholder perceptions. PREMOM II is a prospective, randomized, multicenter follow-up study that was performed to explore these promising results.

Methods: After providing written consent, 3922 pregnant women aged ≥18 years who are at increased risk of developing GHD will be randomized (1:1:1 ratio) to (a) conventional care (control group), (b) a patient self-monitoring group, and (c) a midwife-assisted RM group. The women in each group will be further divided (1:1 ratio) to evaluate the outcomes of targeted or non-targeted (conventional) antihypertensive medication. Women will be recruited in five hospitals in Flanders, Belgium: Ziekenhuis Oost-Limburg, Universitaire Ziekenhuis Antwerpen, Universitaire Ziekenhuis Leuven, AZ Sint Jan Brugge-Oostende, and AZ Sint Lucas Brugge. The primary outcomes are: (1) numbers and types of prenatal visits; (2) maternal outcomes; (3) neonatal outcomes; (4) the applicability and performance of RM; and (5) compliance with RM and self-monitoring. The secondary outcomes are: (1) cost-effectiveness and willingness to pay; (2) patient-reported outcome measures (PROMS) questionnaires on the experiences of the participants; and (3) the maternal and perinatal outcomes according to the type of antihypertensive medication. Demographic, and maternal and neonatal outcomes are collected from the patients' electronic records. Blood pressure and compliance rate will be obtained from an online digital coordination platform for remote data handling. Information about the healthcare-related costs will be obtained from the National Coordination Committee of Belgian Health Insurance Companies (Intermutualistisch Agentschap). PROMS will be assessed using validated questionnaires.

Discussion: To our knowledge, this is the first randomized trial comparing midwife-assisted RM and self-monitoring of prenatal blood pressure versus conventional management among women at increased risk of GHD. Positive results of this study may lead to a practical framework for caregivers, hospital management, and payers to introduce RM into the prenatal care programs of high-risk pregnancies.

Trial registration: This study was registered on clinicaltrials.gov , identification number NCT04031430. Registered 24 July 2019, https://ichgcp.net/clinical-trials-registry/NCT04031430?cond=premom+ii&draw=2&rank=1 .

Keywords: Gestational hypertensive disorders; Pre-eclampsia; Remote monitoring.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Workflow of PREMOM I
Fig. 2
Fig. 2
Randomization process and study flow
Fig. 3
Fig. 3
Timeline table – SPIRIT. G = gravidity; FMF = Fetal Medicine Foundation tool

References

    1. Devlieger R, Martens E, Martens G, Van Mol C, Cammu H. Perinatale activiteiten in Vlaanderen 2015. Brussel: SPE; 2016.
    1. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. 2020. . Accessed 22 July 2020.
    1. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2:CD002252.
    1. Ankumah NA, Cantu J, Jauk V, Biggio J, Hauth J, Anders W, et al. Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation. Obstet Gynecol. 2014;123(5):966–972. doi: 10.1097/AOG.0000000000000205.
    1. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;3:CD002863.
    1. Barton JR, O’brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol. 2001;184(5):979–983. doi: 10.1067/mob.2001.112905.
    1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565. doi: 10.1136/bmj.38380.674340.E0.
    1. Tranquili AL, Dekker GA, Magee L, Roberts JM. The classification, diagnosis and Management of the Hypertensive Disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;106(45):7.
    1. Mol B, Roberts C, Thangaratinam S, Magee L, De Groot C, Hofmeyr G. Pre-eclampsia. Lancet. 2016;387(10022):999–1011. doi: 10.1016/S0140-6736(15)00070-7.
    1. Rath W, Fischer T. The diagnosis and treatment of hypertensive disorders of pregnancy. Dtsch Arztebl Int. 2009;106(45):733–8.
    1. Rosner BI, Gottlieb M, Anderson WN. Effectiveness of an automated digital remote guidance and telemonitoring platform on costs, readmissions, and complications after hip and knee arthroplasties. J Arthroplasty. 2018;33(4):988–96.e4.
    1. Clarke M, Fursse J, Connolly N, Sharma U, Jones R. Evaluation of the National Health Service (NHS) direct pilot Telehealth program: costeffectiveness analysis. Telemed J E Health. 2018;24(1):67–76.
    1. Lanssens D, Vonck S, Storms V, Thijs IM, Grieten L, Gyselaers W. The impact of a remote monitoring program on the prenatal follow-up of women with gestational hypertensive disorders. J Med Internet Res. 2018;223:72–78.
    1. Lanssens D, Vandenberk T, Smeets CJP, De Cannière H, Molenberghs G, Van Moerbeke A, et al. Remote monitoring of hypertension diseases in pregnancy: a pilot study. JMIR Mhealth Uhealth. 2017;5(3):e25. doi: 10.2196/mhealth.6552.
    1. Marko KI, Krapf JM. Testing the feasibility of remote patient monitoring in prenatal care using a mobile app and connected devices: a prospective observational trial. JMIR Res Protoc. 2016;5(4):e200.
    1. Wijsman LW, Richard E. Evaluation of the use of home blood pressure measurement using mobile phone-assisted technology: the ivitality proof-ofprinciple study. JMIR Mhealth Uhealth. 2016;4(2):e67.
    1. Milani RV, Lavie CJ, Bober RM, Milani AR, Ventura HO. Improving hypertension control and patient engagement using digital tools. Am J Med. 2017;130(1):14–20. doi: 10.1016/j.amjmed.2016.07.029.
    1. Li WW, Lai WS. The use of telemedicine interventions to improve hypertension management among racial ethnic minorities: a systematic review. Hu Li Za Zhi. 2016;63(4):25–34.
    1. Omboni S, Caserini M, Coronetti C. Telemedicine and M-health in hypertension management: technologies, applications and clinical evidence. High Blood Press Cardiovasc Prev. 2016;23(3):187–196. doi: 10.1007/s40292-016-0143-6.
    1. Goldberg EM, Levy PD. New approaches to evaluating and monitoring blood pressure. Curr Hypertens Rep. 2016;18(6):49. doi: 10.1007/s11906-016-0650-9.
    1. Rhoads SJ, Serrano CI, Lynch CE, Ounpraseuth ST, Gauss CH, Payakachat N, et al. Exploring implementation of m-health monitoring in postpartum women with hypertension. Telemed J E Health. 2017;23(10):833–841. doi: 10.1089/tmj.2016.0272.
    1. Hirshberg A, Downes K, Srinivas S. Comparing standard office-based follow-up with text-based remote monitoring in the management of postpartum hypertension: a randomised clinical trial. BMJ Qual Saf. 2018;27(11):871–877. doi: 10.1136/bmjqs-2018-007837.
    1. Lanssens D, Vandenberk T, Smeets C, De Cannière H, Vonck S, Claessens J, et al. Cost- analysis of prenatal remote monitoring of women with gestational hypertensive diseases. J Med Internet Res. 2018;20(3):e102. doi: 10.2196/jmir.9552.
    1. Lanssens D, Vonck S, Vandenberk T, Schraepen C, Storms V, Thijs IM, et al. A prenatal remote monitoring program in pregnancies complicated with gestational hypertensive disorders: what are the contributors to the cost savings? Telemed J E Health. 2019;25(8):686–92.
    1. Imershein AW, Turner C, Wells JG, Pearman A. Covering the costs of care in neonatal intensive care units. Pediatrics. 1992;89(1):56–61.
    1. Pourat N, Martinez AE, Jones JM, Gregory KD, Korst L, Kominski GF. Costs of gestational hypertensive disorders in California: hypertension, preeclampsia, and Eclampsia. Los Angles: UCLA Center for Health Policy Research; 2013.
    1. Lanssens D, Vandenberk T, Lodewijckx J, Peeters T, Thijs IM, Grieten L, et al. The perceptions of midwives, obstetricians, and recently delivered mothers to remote monitoring for prenatal care. J Matern Fetal Neonatal Med. 2019;21(4):e10887.
    1. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2018;52:186–195. doi: 10.1002/uog.19112.
    1. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco MC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–622. doi: 10.1056/NEJMoa1704559.
    1. Tomsin K, Mesens T, Molenberghs G, Peeters L, Gyselaers W. Characteristics of heart, arteries, and veins in low and high cardiac output preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):218–222. doi: 10.1016/j.ejogrb.2013.03.016.
    1. Vonck S, Staelens A, Mesens T, Tomsin K, Gyselaers W. Hepatic hemodynamics and fetal growth: a relationship of interest for further research. PLoS One. 2014;9(12):e115594.
    1. Mahendru AA, Foo FL, McEniery CM, Everett TR, Wilkinson IB, Lees CC. Change in maternal cardiac output from preconception to mid-pregnancy is associated with birth weight in healthy pregnancies. Ultrasound Obstet Gynecol. 2017;49(1):78–84.
    1. Ferrazzi E, Stampalija T, Monasta L, Di Martino D, Vonck S, Gyselaers W. Maternal hemodynamics: a method to classify hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2018;218(1):124.e1–124e11. doi: 10.1016/j.ajog.2017.10.226.
    1. Tay J, Foo L, Masini G, Bennett PR, McEniery CM, Wilkinson IB, et al. Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: insights from a prospective study. Am J Obstet Gynecol. 2018;218(5):517.e1–517e12. doi: 10.1016/j.ajog.2018.02.007.
    1. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94(6):978–984.
    1. Easterling TR, Benedetti TJ, Schmucker BC, Millard SP. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol. 1990;76(6):1061–1069.
    1. Cornette J, Duvekot JJ, Roos-Hesselink JW, Hop WC, Steegers EA. Maternal and fetal haemodynamic effects of nifedipine in normotensive pregnant women. BJOG. 2011;118(4):510–540. doi: 10.1111/j.1471-0528.2010.02794.x.
    1. Stott D, Bolten M, Paraschiv D, Papastefanou I, Chambers JB, Kametas NA. Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy. Ultrasound Obstet Gynecol. 2017;49(1):85–94. doi: 10.1002/uog.17335.
    1. Duan L, Ng A, Chen W, Spencer HT, Lee MS. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich). 2018;20(11):1603–9.
    1. Vinayagam D, Thilaganathan B, Stirrup O, Mantovani E, Khalil A. Maternal hemodynamics in normal pregnancies: reference ranges and the role of maternal characteristics. Ultrasound Obstet Gynecol. 2018;51(5):665–671. doi: 10.1002/uog.17504.
    1. Het InterMutualistisch Agentschap, IMA (2019, 26 november). Het InterMutualistisch Agentschap. . Accessed 22 July 2020.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren